Identification of PIK3CG and SYK as Dual Therapeutic Targets in Parkinson's Disease Microglia via Single-Cell RNA Sequencing and Computational Drug Repurposing
Fuente:
Zenodo
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866902005914533888 |
|---|---|
| author | Ritschel, Glen Charles Claude |
| author_facet | Ritschel, Glen Charles Claude |
| contents | <p>Provisional patent specification filed with the United States Patent and Trademark Office (USPTO) by Glen Charles Ritschel, Ritschel Research, Tega Cay, South Carolina (Micro-Entity; Application # 64/015,045; filed March 24, 2026). This specification discloses a computational drug repurposing method applied to single-cell RNA sequencing data from Parkinson's Disease patient substantia nigra (GSE157783; Smajić et al., Brain 2022; 40,452 cells; 11 PD donors). A single dominant microglial cluster (cluster 3; P2RY12⁺, CX3CR1⁺, CSF1R⁺) was identified, and differential expression analysis yielded 2,638 microglial-enriched genes. Seven ChEMBL-tractable targets were extracted (SYK, PIK3CG, CD86, CSF3R, CLEC7A, PTPRC, CX3CR1), and 8,793 unique compounds were screened and verified as NOVEL_ALL by USPTO prior art search. Top dual-target PIK3CG/SYK leads include APITOLISIB (CHEMBL1922094; final score 58.8), LESTAURTINIB (CHEMBL603469; 58.0), and FEDRATINIB (CHEMBL1287853; 42.8). A cross-disease SYK convergence signal was identified between this Parkinson's Disease dataset and an independent Alzheimer's Disease microglial dataset. Pipeline code: <a href="https://github.com/glenritschel/parkinsons-scrna">https://github.com/glenritschel/parkinsons-scrna</a></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19210175 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Identification of PIK3CG and SYK as Dual Therapeutic Targets in Parkinson's Disease Microglia via Single-Cell RNA Sequencing and Computational Drug Repurposing Ritschel, Glen Charles Claude Parkinson's Disease microglia scRNA-seq single-cell RNA sequencing drug repurposing PIK3CG SYK kinase inhibitor neuroinflammation substantia nigra APITOLISIB LESTAURTINIB FEDRATINIB computational biology provisional patent USPTO ChEMBL GSE157783 Ritschel Research <p>Provisional patent specification filed with the United States Patent and Trademark Office (USPTO) by Glen Charles Ritschel, Ritschel Research, Tega Cay, South Carolina (Micro-Entity; Application # 64/015,045; filed March 24, 2026). This specification discloses a computational drug repurposing method applied to single-cell RNA sequencing data from Parkinson's Disease patient substantia nigra (GSE157783; Smajić et al., Brain 2022; 40,452 cells; 11 PD donors). A single dominant microglial cluster (cluster 3; P2RY12⁺, CX3CR1⁺, CSF1R⁺) was identified, and differential expression analysis yielded 2,638 microglial-enriched genes. Seven ChEMBL-tractable targets were extracted (SYK, PIK3CG, CD86, CSF3R, CLEC7A, PTPRC, CX3CR1), and 8,793 unique compounds were screened and verified as NOVEL_ALL by USPTO prior art search. Top dual-target PIK3CG/SYK leads include APITOLISIB (CHEMBL1922094; final score 58.8), LESTAURTINIB (CHEMBL603469; 58.0), and FEDRATINIB (CHEMBL1287853; 42.8). A cross-disease SYK convergence signal was identified between this Parkinson's Disease dataset and an independent Alzheimer's Disease microglial dataset. Pipeline code: <a href="https://github.com/glenritschel/parkinsons-scrna">https://github.com/glenritschel/parkinsons-scrna</a></p> |
| title | Identification of PIK3CG and SYK as Dual Therapeutic Targets in Parkinson's Disease Microglia via Single-Cell RNA Sequencing and Computational Drug Repurposing |
| topic | Parkinson's Disease microglia scRNA-seq single-cell RNA sequencing drug repurposing PIK3CG SYK kinase inhibitor neuroinflammation substantia nigra APITOLISIB LESTAURTINIB FEDRATINIB computational biology provisional patent USPTO ChEMBL GSE157783 Ritschel Research |
| url | https://doi.org/10.5281/zenodo.19210175 |